Impact of Additional Copies of Chromosome 1 Long Arm in Multiple Myeloma Patients
Key Findings:
Patients with amplification (Amp1q, ≥4 copies of 1q) or gain (Gain1q, 3 copies of 1q) of chromosome 1 long arm (1q) may experience different outcomes and biology compared to those with normal 1q.
Presence of Amp1q significantly hampered median progression-free survival (PFS), while Gain1q patients also had a shorter PFS compared to those with normal 1q.
Amp1q patients with additional poor prognostic factors or failure to achieve MRD negativity had a median PFS of less than 12 months.
Treatment with carfilzomib-lenalidomide-dexamethasone plus autologous stem cell transplantation improved the adverse effect of Gain1q but not Amp1q.
Transcriptomic data indicated deregulation in apoptosis signaling, p38 MAPK signaling, and Myc-related genes associated with additional 1q copies.
Practical Solutions:
Using AI-driven platforms, such as our DocSym, to consolidate standards, protocols, and research into a single accessible knowledge base for clinicians can extend the benefits of clinical trials into everyday medical practice.
Streamlining operations through mobile apps that support scheduling, monitoring treatments, and telemedicine can make it easier to manage patient care and expand services digitally, enhancing workflows and improving patient outcomes.
By leveraging AI, clinics can reduce paper routine and enhance their overall workflows, contributing to better patient care and outcomes.
Value:
Understanding the impact of additional 1q copies in MM patients can guide treatment decisions and predict patient outcomes, ultimately improving care strategies and patient survival rates.
Adopting AI-driven platforms and mobile apps can streamline healthcare operations, making it easier for clinicians to deliver high-quality care and expanding healthcare services, ultimately contributing to better patient outcomes.
Learn more about how AI can support clinical workflows and improve patient care at aidevmd.com.
